Peter Pizzo - Alimera Sciences Independent Director
| ALIM Stock | USD 3.63 0.04 1.11% |
Director
Mr. Peter J. Pizzo, III is an Independent Director of the company, Mr. Pizzo was a member of the Board since April 2010. Since 2005, Mr. Pizzo has served as the Vice President, Finance and Chief Financial Officer of Carticept Medical, Inc., a private medical device company, and since its spinout from Carticept in December 2011, as Vice President, Finance and Chief Financial Officer of Cartiva, Inc., a private orthopedic medical device company. From 2002 until its sale in 2005, Mr. Pizzo served as the Vice President, Finance and Chief Financial Officer of Proxima Therapeutics, Inc., a private medical device company that developed and marketed local radiation delivery systems for the treatment of solid cancerous tumors. From 1996 to 2001, Mr. Pizzo worked for Serologicals Corporationrationration, a publicly traded global provider of biological products to life science companies, ultimately serving as Vice President of Finance and Chief Financial Officer. From 1995 to 1996, Mr. Pizzo served as Vice President of Administration and Controller of ValueMark Healthcare Systems, Inc., a privately held owneroperator of psychiatric hospitals. From 1992 until its sale in 1995, Mr. Pizzo served in various senior financial positions at Hallmark Healthcare Corporationrationration, a publicly traded hospital management company, most recently as Treasurer since 2010.
| Age | 50 |
| Tenure | 14 years |
| Address | 6310 Town Square, Alpharetta, GA, United States, 30005 |
| Phone | 678 990 5740 |
| Web | https://alimerasciences.com |
Alimera Sciences Management Efficiency
The company has return on total asset (ROA) of (0.0123) % which means that it has lost $0.0123 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5876) %, meaning that it created substantial loss on money invested by shareholders. Alimera Sciences' management efficiency ratios could be used to measure how well Alimera Sciences manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of April 2024, Return On Tangible Assets is likely to drop to -0.38. In addition to that, Return On Capital Employed is likely to drop to -0.01. At this time, Alimera Sciences' Asset Turnover is very stable compared to the past year.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Frederick Craves | Journey Medical Corp | 72 | |
| David Cohen | Journey Medical Corp | 53 | |
| Heung Tsui | China Pharma Holdings | 56 | |
| Jake Nunn | Journey Medical Corp | 47 | |
| Yingwen Zhang | China Pharma Holdings | 68 | |
| Kathleen Sebelius | Journey Medical Corp | 69 | |
| Baowen Dong | China Pharma Holdings | 72 | |
| Gene Bennett | China Pharma Holdings | 66 | |
| Matthew Fust | Journey Medical Corp | 53 | |
| Mark McDade | Journey Medical Corp | 62 | |
| Scott LLB | Lucy Scientific Discovery | 54 | |
| William Ringo | Journey Medical Corp | 72 | |
| Eugene Bauer | Journey Medical Corp | 75 | |
| Jun Zheng | China SXT Pharmaceuticals | 46 | |
| Emmanuel Caeymaex | Journey Medical Corp | 46 | |
Management Performance
| Return On Equity | -1.59 | ||||
| Return On Asset | -0.0123 |
Alimera Sciences Leadership Team
Elected by the shareholders, the Alimera Sciences' board of directors comprises two types of representatives: Alimera Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alimera. The board's role is to monitor Alimera Sciences' management team and ensure that shareholders' interests are well served. Alimera Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alimera Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Snisarenko, Director | ||
| Christopher Visick, General VP | ||
| Todd Wood, President Operations | ||
| James Largent, Independent Director | ||
| Peter Pizzo, Independent Director | ||
| Calvin Roberts, Independent Director | ||
| Samer Kaba, Chief Medical Officer | ||
| Mary Szela, Director | ||
| Phil Jones, CFO | ||
| Elliot CPA, CFO Treasurer | ||
| David Burke, Vice President | ||
| Philip Ashman, Sr. VP and European Managing Director | ||
| Jason Werner, Chief Officer | ||
| David Holland, Co-Founder and Sr. VP of Sales and Marketing | ||
| Garheng Kong, Independent Director | ||
| Kenneth Green, Chief Scientific Officer and Sr. VP | ||
| Richard Eiswirth, Pres and CFO | ||
| Brian Halak, Independent Director | ||
| Daniel Myers, President CEO, Director | ||
| Charles Myers, NonEx Consultant | ||
| Mark Brooks, Independent Director | ||
| Rich Cockrell, President | ||
| David MD, Chief Specialist |
Alimera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alimera Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.59 | ||||
| Return On Asset | -0.0123 | ||||
| Profit Margin | (0.25) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 240.68 M | ||||
| Shares Outstanding | 52.35 M | ||||
| Shares Owned By Insiders | 8.75 % | ||||
| Shares Owned By Institutions | 91.95 % | ||||
| Number Of Shares Shorted | 108.76 K | ||||
| Price To Earning | 1.65 X |
Pair Trading with Alimera Sciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alimera Sciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alimera Sciences will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Alimera Sciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alimera Sciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alimera Sciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alimera Sciences to buy it.
The correlation of Alimera Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alimera Sciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alimera Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alimera Sciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alimera Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Alimera Stock, please use our How to Invest in Alimera Sciences guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Alimera Stock analysis
When running Alimera Sciences' price analysis, check to measure Alimera Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alimera Sciences is operating at the current time. Most of Alimera Sciences' value examination focuses on studying past and present price action to predict the probability of Alimera Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alimera Sciences' price. Additionally, you may evaluate how the addition of Alimera Sciences to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is Alimera Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alimera Sciences. If investors know Alimera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alimera Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.84) | Revenue Per Share 3.159 | Quarterly Revenue Growth 0.875 | Return On Assets (0.01) | Return On Equity (1.59) |
The market value of Alimera Sciences is measured differently than its book value, which is the value of Alimera that is recorded on the company's balance sheet. Investors also form their own opinion of Alimera Sciences' value that differs from its market value or its book value, called intrinsic value, which is Alimera Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alimera Sciences' market value can be influenced by many factors that don't directly affect Alimera Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alimera Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alimera Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alimera Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.